The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 217-220

  Estrella, Michelle M ^a   Parekh, Rulan S ^a,b,c   Abraham, Alison ^c   Astor, Brad C ^a,c   Szczech, Lynda A ^d   Anastos, Kathryn ^e   Dehovitz, Jack A ^f   Merenstein, Daniel J ^g   Pearce, C Leigh ^h   Tien, Phyllis C ⁱ   Cohen, Mardge H ^j   Gange, Stephen J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j RUSH MEDICAL COLLEGE   (United States)

more..

Author keywords

Antiretroviral therapy; HIV; Kidney disease; Mortality; WIHS

Indexed keywords

ALBUMIN; CREATININE; HEPATITIS C ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RACE; SURVIVAL TIME; CHRONIC KIDNEY FAILURE; COMPLICATION; CONFIDENCE INTERVAL; HIV INFECTIONS; KIDNEY FUNCTION TEST; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVALS; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 77957321844     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e674f4     Document Type: Article

References (17)

1. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199-1206.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society- USA panel. JAMA. 2008;300:555-570.
3. Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis. 2006;43:377-380.
4. Fine DM, Garg N, Haas M, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol. 2007;2: 1125-1130.
5. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study.WIHS collaborative study group. Epidemiology. 1998;9:117-125.
6. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11:115A.
7. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
8. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91-98.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296-1305.
10. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the united states. J Am Soc Nephrol. 2002;13:745-753.
11. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006;17:2034-2047.
12. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
13. Rodriguez RA, Mendelson M, O'Hare AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14:1307-1313.
14. Choi AI, Rodriguez RA, Bacchetti P, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007;45:1633-1639.
15. Gandhi M, Gange SJ, Ponath J, et al. Identification of novel factors that influence atazanavir exposure in a diverse population of HIV-infected women under conditions of actual use. 17th Conference of Retroviruses and Opportunistic Infections. San Francisco, CA; February 16-19, 2010.
16. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003; 63:1121-1129. (Pubitemid 36315592)
17. Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a wellcharacterized HIV-infected population. Nephron Clin Pract. 2009;111: c39-c48.